Outlook Therapeutics, Inc. Cash Flow Statement
OTLK|6 years of annual SEC 10-K data (FY2016-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Outlook Therapeutics, Inc. used $69M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|
| Net Income | -$75.4M | -$34.5M | -$30.1M | -$38.8M | -$53.3M | -$47.4M |
| Depreciation & Amortization | $113.9K | $3.4M | $3.1M | $2.7M | $2.4M | $1.8M |
| Operating Cash Flow | -$68.8M | -$32.3M | -$33.0M | -$15.5M | -$45.5M | -$27.5M |
| Capital Expenditures | - | $437.3K | $2.8M | $292.1K | $1.1M | $8.8M |
| Free Cash Flow | - | -$32.7M | -$35.8M | -$15.8M | -$46.6M | -$36.3M |
| FCF Margin | - | -401.8% | -1160.2% | -414.5% | -1563.3% | -695.1% |